New drug RG002C0106 put to the test in healthy volunteers
NCT ID NCT06494527
First seen Mar 11, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This early-stage study tests whether a new drug, RG002C0106, is safe and tolerable in healthy adults aged 18 to 60. Thirty volunteers will receive either the drug or a placebo, and researchers will monitor for side effects. The goal is to gather safety information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 101125, China
Conditions
Explore the condition pages connected to this study.